Up Front MattersBrief Reviews

The Evolving Complexity of the Podocyte Cytoskeleton

Christoph Schell and Tobias B. Huber
JASN November 2017, 28 (11) 3166-3174; DOI: https://doi.org/10.1681/ASN.2017020143

Abstract

Podocytes exhibit a unique cytoskeletal architecture that is fundamentally linked to their function in maintaining the kidney filtration barrier. The cytoskeleton regulates podocyte shape, structure, stability, slit diaphragm insertion, adhesion, plasticity, and dynamic response to environmental stimuli. Genetic mutations demonstrate that even slight impairment of the podocyte cytoskeletal apparatus results in proteinuria and glomerular disease. Moreover, mechanisms underpinning all acquired glomerular pathologies converge on disruption of the cytoskeleton, suggesting that this subcellular structure could be targeted for therapeutic purposes. This review summarizes our current understanding of the function of the cytoskeleton in podocytes and the associated implications for pathophysiology.

Form Follows Function—Composition and Structure of the Podocyte Cytoskeleton

Podocytes exhibit a complex cellular morphology characterized by a sophisticated cell polarity organization and an extensive network of protrusions which extend from a primary process into numerous secondary projections called foot processes. The latter not only surround glomerular capillaries but also interlink neighboring podocytes via slit diaphragms1–3 (see Figure 1). Because of the anatomic position on the outside of the glomerular capillary, podocytes are exposed to tremendous physical forces, which are required for efficient glomerular filtration. Hence, foot processes are not only involved in the formation of the filtration barrier, but are also essential for increasing the surface, thereby mediating efficient attachment to the glomerular basement membrane.4,5 Retraction and simplification of the podocyte foot process network (termed foot process effacement) is the common feature in all glomerular diseases.6,7 Early work from the 1980s employing immuno-gold–labeled electron microscopy demonstrated that primary and secondary processes have unique cytoskeletal characteristics and components. Primary processes are predominantly on the basis of intermediate filaments (IFs) and microtubules (MT), whereas secondary processes mainly rely on an actin cytoskeleton.8,9

Figure 1.
Figure 1.

Podocytes rely on a diverse cytoskeletal repertoire to maintain their complex morphology. (A) During development podocytes undergo a dramatic change in morphology, characterized by increasing basal specification ultimately leading to the complex podocyte foot process (FP) network. (B) Schematic depiction of the organization and distribution of the podocyte cytoskeleton: within primary processes mainly IFs and tubulin networks stabilize the morphology (insert, primary processes [PP]). Secondary processes are mainly composed of different actin cytoskeleton structures (insert, FPs, see also C). (C) In the upper panel, FPs are schematically characterized under physiologic conditions: at least two different actin networks are discernible, a central actin bundle within each FP and the cortical actin network beneath the plasma membrane (also connected to adhesion receptors). In the lower panel, FP effacement is depicted as a simplification and retraction of individual FPs. This process is accompanied by a redistribution of the aforementioned actin networks, characterized by the occurrence of a prominent actin accumulation parallel to the glomerular basement membrane (described also as an “actin mat”). Aside from reorganization of the actin network, adhesion receptors are also dissolved resulting in progressive detachment of FPs and podocytes.

The Microtubule Cytoskeleton

Microtubules (MTs) are oriented structures composed of α/β-tubulin subunits, characterized by a fast-growing (plus) end and a slow-growing (minus) pole.10 MTs are highly dynamic structures, involved in a variety of cell biologic processes such as migration and mitosis, as well as cilia formation.11–13 Early studies using in vitro cultured immortalized podocytes suggested that MT-motor proteins CHO/MKLP1 and protein phosphatase 2A (PP2A) are involved in podocyte primary process formation and orientation.14,15 Given the peculiar similarity in terms of cellular morphology between polarized neurons and podocytes (prominent cell body, polarized protrusion network1), it is of special interest that a series of mutations involving certain tubulin isotypes result in neurodevelopmental disorders with a variety of phenotypes, ranging from cortical malformations to degeneration of axons.16–18 Interestingly, in none of those reported genetic syndromes was a kidney or particular podocyte phenotype reported. To date, there is one study employing a mouse model mimicking human TUBB2B mutations (resulting in asymmetric polymicrogyria and epilepsy19) reporting glomerular maturational defects.20 However, this model shows embryonic lethality and ultrastructural studies revealed that despite impaired podocyte maturation (cuboidal shape, occludens type junctions), a podocyte foot process network can be formed. Certainly, more work is needed to clarify the structural effect of the tubulin cytoskeleton for podocyte processes. Aside from the core MT cytoskeleton, there is an array of MT-associated proteins (MAPs) involved in stabilizing, bundling, or severing of MTs. A series of studies focused so far on the expression of different MAPs such as MAP4, MAP3, and lately MAP1B in podocytes.21–23 Although MAP1B showed a high expressional enrichment in podocytes and colocalized with the MT network, the constitutive knockout for MAP1B did not result in any overt glomerular phenotype under physiologic conditions (in contrast to neurons23).

Intermediate Filaments

The second group of cytoskeletal constituents particularly detected within primary processes is the class of intermediate filaments (IFs). In contrast to the actin and MT cytoskeleton, which is composed of single protein type polymers, IFs represent a heterogeneous group organized due to structural homologies into six classes. On the basis of immunohistochemistry studies on various murine experimental models, as well as human samples, it was unequivocally demonstrated that podocytes express the class III type IF vimentin.24,25 Moreover, several studies attempted to characterize alterations in the expression pattern of detected IFs under diseased conditions, showing that the typical muscle cell marker desmin appears to be upregulated upon podocyte stress or damage.26,27 So far, there is only limited evidence directly demonstrating the effect and role of vimentin and desmin for podocyte function, whereas IFs have been demonstrated to regulate the cellular elasticity in isolated glomeruli.28 Surprisingly, knockout models for either desmin or vimentin do not, however, result in any podocyte phenotype.29,30 The pronounced change in the expression pattern of IFs (re-expression of desmin) is generally accepted as a surrogate marker for a phenotypic switch of podocytes under pathologic conditions, often termed as epithelial-mesenchymal transition.31,32 However, one should be cautious to use this term for what rather represents a loss of podocyte differentiation in response to injury.33 Aside from typical mesenchymal IFs (class III), podocytes also express the class VI IF nestin, usually described as a characteristic marker of neuronal stem/progenitor cell populations and also found in several cancer entities.34,35 From studies using neuronal progenitor cells and the nestin knockout model, a cytoprotective, antiapoptotic function was deduced.36,37 This beneficial function is at least partially mediated via an interaction between nestin and the cyclin-dependent kinase 5 (CDK5).36 A similar observation was recently made in podocytes, especially when challenged under high glucose conditions.38–40 In summary, IFs do not appear as predominant stabilizing cytoskeletal components of the podocyte, but might rather be involved in signaling functions or intracellular sorting/transport processes as shown in different other cell types.41

Actin Cytoskeleton

In contrast to the two aforementioned cytoskeletal components, the actin cytoskeleton that constantly undergoes polymerization and severing, shows a rather exclusive localization within secondary processes (FPs).9 Actin filaments are composed of globular actin monomers and the efficient polymerization process involves ATP usage.42 Several polymerizing and severing proteins are known (before excellent review see42) to modulate the composition of the actin cytoskeleton. The ARP2/3 complex plays a particular role, because this molecular machinery efficiently introduces new branches on pre-existing filaments, a process essentially required for the formation of lamellipodia in vitro.43 Early studies using electron microscopy could reveal that even within podocyte secondary processes apparently different actin pools might be present. In the center of each FP an electron dense actin accumulation was detected and interpreted as the correlate of central actin bundles.44,45 Beneath the curved plasma membrane of FPs a dense actin network was described and assumed to represent branched subcortical actin meshwork (Figure 1). On the basis of these observations it was proposed that the central actin bundles might be involved in generating tensional forces, whereas the branched meshwork is essentially required to maintain the complex morphology of podocyte foot processes.45 Foot process effacement as the common pattern of podocyte injury involves active remodeling of the actin cytoskeleton46 often including the formation of a flat actin mat that is thought to provide increased adhesion forces.46 Recent in vitro studies advanced our understanding of the architecture of the actin cytoskeleton.47,48 However, advances in new super resolution microscopy techniques such as stimulated emission depletion or stochastic optical reconstruction microscopy now offer new avenues to fully understand the complexity, composition, and dynamics of the podocyte actin cytoskeleton in vivo.49

Additional insights into the structural and functional relation of FPs have come to light through the study of dramatic changes in podocyte morphology which take place during glomerular development, where cuboidal nonfiltering podocytes differentiate into arborized octopus-like filtering cells50 (Figure 1). In this context, a series of studies demonstrated the requirement of the aPKC/PAR complex for correct podocyte morphogenesis.51–53 The importance of podocyte polarity signaling is also supported by the high level of redundancy of the involved molecules.54–56 In addition, loss-of-function mutations in the gene encoding the polarity protein CRUMBS2 have been shown to result in steroid-resistant nephrotic syndrome.57

From Genes to Function—Lessons from Genetic Syndromes Affecting the Podocyte Cytoskeleton

The list of causal mutations for glomerular diseases has rapidly expanded over the last few years, driven by the development of accurate sequencing platforms. Not surprisingly, cytoskeletal proteins account for a significant proportion of the proteins that are involved in hereditary glomerular diseases (see Figure 2, Table 1). One of the first discovered cytoskeletal linked proteins causing specific podocyte dysfunction was actinin-4 (ACTN4).58 Whereas α-actinin is required to link actin filaments to Z-lines in striated muscles,59 the so-called nonsarcomeric actinins, like actinin-1 and ACTN4, are differentially expressed in nonmuscle cells where they crosslink stress fibers. Interestingly, mutations in ACTN4 cause a wide range of functional impairments ranging from decreased protein stability,60 gain-of-function, subcellular mislocalization, and increased F-actin binding capacity.61 These alterations translate into impaired cytoskeletal dynamics characterized by decreased cellular spreading and attenuation of podocyte migration.62 In line with the recent discovery of mutant ACTN4 forms showing decreased protein stability and protein levels, lack of ACTN4 in mice also results in proteinuria and an FSGS-like phenotype.63 In addition, ACTN4 mutations may also have nonstructural functions such as transcriptional regulation contributing to glomerular disease.64

Figure 2.
Figure 2.

Interacting signaling cascades determine podocyte cytoskeletal stability and cell-matrix interaction. (A) Various modulators of the podocyte cytoskeleton and their potential therapeutic approach (yellow indicates proteins with a proven genetic disease background; red indicates available drugs or pharmacologic drug classes). (B) The podocyte-specific FA component EPB41L5 titrates actomyosin contractility via recruitment of the small GTPase ARHGEF18, thereby influencing podocyte adhesion and attachment. Actn4, Actinin-4; ANLN, Anilin; EPB41L5, Erythrocyte Membrane Protein Band 4.1 Like 5; FAK, Focal Adhesion Kinase; INF2, Inverted formin 2; ITGα3β1, Integrin α3β1; ROCK, Rho-associated protein kinase.

View this table:
Table 1.

Cytoskeleton-associated mutations related to SRNS/FSGS phenotypes

The formin protein family member inverted formin 2 (INF2) is another cytoskeletal gene prominently involved in podocyte disease.65 Formin proteins are key regulators of actin polymerization.65 Interestingly, the majority of identified mutations within INF2 are localized in the autoinhibitory domain (diaphanous inhibitory domain), implying increased activity of this protein causes glomerular dysfunction.66 Moreover, a recent study demonstrated that INF2 interacts with the actin-modifying proteins profilin and the capping protein CAPZ, whereas INF2 mutations impaired these interactions.67 Interestingly, INF2 mutations also lead to complex neurologic disease phenotypes such as Charcot–Marie–Tooth neuropathy.68 Because INF2 might also modulate mitochondrial dynamics,69 these observations imply the presence of a diverse range of disease-associated mechanisms that selectively operate in a cell-specific manner.1,4,70

Further genetic studies demonstrated that missense mutations within the actin binding protein anilin segregate with human FSGS.71 Mechanistically, these mutations interfered with the interaction of anilin with CD2AP. CD2AP mutations have also been reported in rare cases of human genetic FSGS72–75 and mouse studies definitively demonstrated the requirement of CD2AP activity in podocytes.72,76 Initially identified as a ligand interacting with T cell CD2 receptor,77 CD2AP supports several functions in podocytes ranging from slit diaphragm signaling78 to glucose transporter trafficking.79 Furthermore, it was shown that CD2AP plays a role in modulating podocyte TGFβ response in order to prevent a proteolytic program that would culminate in decreased levels of essential cytoskeletal components such as dynamin and synaptopodin.80 A similar cellular phenotype was reported in the case of missense mutations of ARHGAP24, a small GTPase modulator which is specifically expressed in podocytes. Recent work showed that these mutations within ARHGAP24 resulted in increased membrane ruffling dynamics, a phenotype which is thought to partially reflect podocyte foot process effacement in vitro.81

Balance Is the Key—Pathophysiologic Concepts of Cytoskeletal Dynamics

Regulatory networks of intrinsic and extrinsic signaling factors tightly control the podocyte cytoskeleton with minor changes shifting the system toward podocyte disease. This was exemplified by mouse models where combined genetic heterozygosity of Cd2ap, Synpo, Fyn proto-oncogene (Fyn), and Neph1 was tested.82 Although heterozygosity of these genes alone did not cause any early-onset phenotype, compound heterozygosity (i.e., combinations of heterozygous mutations) resulted in FSGS-like glomerular disease suggesting synergistic effects of genetic modifiers to reach the threshold of podocyte disease.82

Podocytes, with their complex interdigitating network of foot processes, are accepted as essentially stationary cells, at least under normal physiologic conditions. This concept was recently supported by elegant in vivo two-photon imaging studies employing zebrafish larvae as a model system.83 Also, under prolonged observation no motile phenotype of podocytes was noted. In contrast, experimental studies performed in mice with the same technical approach could visualize a migrating podocyte phenotype under stressed conditions (unilateral ureteral obstruction and adriamycin nephropathy).84 On the basis of in vitro studies, a transition to a motile state has been considered as a pathologic condition to explain the effects of foot process effacement. Treatment of podocytes with nephrotoxic substances such as puromycin aminonucleoside resulted in increased migration.85 Furthermore, more recent studies proposed that rapid oscillations at the leading edge of the cell may reflect cytoskeletal instability, which normally has to be controlled to maintain the complex morphology of podocyte foot processes.81,86 In previous studies the GTPases RhoA, RAC1, and CDC42 were identified as the molecular machinery defining podocyte cytoskeletal stability.87–89 By deleting podocyte GTPases (specifically each GTPase), it was demonstrated that only CDC42 loss resulted in a profound podocyte phenotype, characterized by massive proteinuria and dramatic ultrastructural abnormalities. On the contrary, loss of RhoA and RAC1 did not result in any overt phenotype, at least under physiologic conditions.88,89 However, knowledge is emerging that titration and balancing of those GTPases appears to play a major decisive role in maintaining podocyte integrity, because, for example, either increased or decreased RAC1 activity lead to proteinuria and podocyte foot process effacement.87,90 This line of thought was substantiated by the identification of causative mutations in ARHGDIA in cases of familial nephrotic syndrome.91 ARHGDIA belongs to the Rho GDI (GDP dissociation inhibitor) family, which ensures that Rho family members are kept in their inactive GDP-bound form within the cytosol. Inhibition of RAC1 overactivation in Arhgdia null mice could suppress the albuminuria phenotype,92 once more emphasizing the importance of balanced cytoskeletal dynamics for podocyte integrity.

Don’t Lose Your Grip—Adhesion as a Key Determinant of Podocyte Function in Health and Disease

Podocyte loss is a key feature in the progression of most glomerular diseases. Because apoptosis is very rarely observed in vivo, the critical step toward podocyte loss can be attributed to the failure of podocyte adhesion.5,93 Integrin heterodimeric receptors represent essential adhesion molecules, exhibiting an exquisite tissue and developmental expression profile.94 The importance of integrin receptors was demonstrated by the identification of mutations within ITGα3 resulting in glomerular and skin disease.95,96 Together with a complex array of adaptor and linker molecules, integrin-based adhesion sites form focal adhesions (FAs).97. FAs are composed of a multiprotein complex consisting of different receptor classes, linker molecules, GTPases, kinases, and phosphatases, collectively known as the adhesome.98,99 FAs not only provide physical linkage via connection of cells to the underlying GBM or ECM, but serve also as signaling hubs by integrating physical and biologic cues and thereby influencing a variety of cellular functions ranging from cell migration to metabolism.97 This concept of reciprocal exchange via FAs was termed outside-in/inside-out signaling and extensively studied in the field of podocyte research (for excellent review see 100). Among the different integrin subunit types, ITGβ1 shows the highest expression in podocytes and a series of studies employing animal models demonstrated the critical role for podocyte maintenance and early development.101,102 More recently, integrin receptors have attracted attention as potential druggable targets in glomerular disease. For example, it was suggested that the induction of B7–1 in podocytes results in a diminished activation of ITGβ1 via competition with talin. On the basis of those assumptions, a recent study tried to treat B7-1 positive patients with FSGS with the CTLA4-modulator abatacept.103 In addition to ITGβ1, increased levels of ITGβ3 activation were identified to play a potential pathogenic role in suPAR-mediated proteinuria.104 Through a series of complementary approaches it was shown that either blocking ITGβ3 activity or inhibiting suPAR-ITGβ3 interaction resulted in a protective effect.104 Although our knowledge about basic constituents of the podocyte adhesome is growing, there is still an urgent need to define the exact composition and modification of this complex in order to identify more specific druggable targets and reliable diagnostic techniques. By combining in vivo quantitative MS analysis with complementary in vitro adhesomics, major progress has recently been made.105 This approach allowed for the identification of a highly selectively expressed FA component of podocytes, the FERM-domain protein EPB41L5. Mechanistically, EPB41L5 recruits the small GTPase ARHGEF18 thereby titrating the activity of the actomyosin cytoskeleton and efficient podocyte adhesion (see Figure 2). Given the highly specific expression, EPB41L5 might serve as a new entry point for innovative diagnostics or therapeutic avenues in the future.

The Actin Cytoskeleton as a Therapeutic Target

The common hallmark of podocyte disease is the uniform stress response characterized by retraction and overt simplification of podocyte foot processes. Some investigators interpret this morphologic change as an adaption of podocytes to withstand altered filtration forces and to increase their adhesiveness,7 but this hypothetic concept is still awaiting experimental confirmation. However, it is accepted that changes in actin cytoskeleton architecture might represent the underlying molecular pattern for this tremendous morphogenetic transformation. Consequently, a recent study demonstrated that stabilizing the actin cytoskeleton is of therapeutic value.106 The same authors identified previously the large GTPase dynamin as an essential component of podocyte function and target in proteinuric kidney diseases, cleaved by cathepsin-L.80,107 Dynamin is itself able to induce actin polymerization.80 The application of a small compound, Ringo or BisT23, stabilizes the conformation of dynamin and thereby prevents the degradation of dynamin even in conditions of high levels of cathepsin. The value of this approach was demonstrated by the successful prevention or at least amelioration of proteinuria in toxic as well as genetic models of podocyte damage.108 Nevertheless, the time of treatment in this preclinical study was of course limited and long-term toxicity effects, as well as side effects, on the organism have to be addressed in future studies.

Conclusion and Outlook

Over the last decades our knowledge concerning the structure and function of the podocyte cytoskeleton increased tremendously. Nevertheless, a fundamental issue is how to translate this insight into treatments for glomerular diseases. And finally, we need a more detailed understanding of how the cytoskeleton itself regulates critical cellular processes such as localized transcription, vesicle trafficking, mitochondrial dynamics, and even nuclear transcription. Better understanding of underlying mechanisms could help in the design and rational development of targeted therapeutic approaches.

Disclosures

None.

Acknowledgments

We apologize to all authors whose work was not cited due to space limitations. We appreciate careful reading of the manuscript by Prof. Ketan Patel, University of Reading, UK, and thank all members of the Huber laboratory for their insightful discussions.

This study was supported by the German Research Foundation (DFG): Collaborative Research Centres 1140 (to T.B.H.) and Collaborative Research Centres 992 (to T.B.H.); the Heisenberg program (to T.B.H.), HU 1016/5-1 and HU 1016/8-1 (to T.B.H.); the European Research Council (ERC grant 616891 to T.B.H.); the Horizon 2020–Innovative Medicines Initiative consortium Biomarker Enterprise To Attack Diabetic Kidney Disease (115974, to T.B.H.); the Bundesministerium für Bildung und Forschung–STOP-Focal Segmental Glomerulosclerosis 01GM1518C (to T.B.H.); the Excellence Initiative of the German Federal and State Governments (Center for Biological Signaling Studies to T.B.H. and the Freiburg Institute for Advanced Studies to T.B.H.); the German Society of Nephrology (Deutsche Gesellschaft für Nephrologie to C.S.); the Berta-Ottenstein program, University of Freiburg (to C.S.); and the Else Kröner Fresenius Stiftung, Nierenfunktionsstörungen als Komplikation von Systemerkrankungen (to C.S. and T.B.H.).

Footnotes

  • Published online ahead of print. Publication date available at www.jasn.org.

References

  1. ↵
    1. Kobayashi N,
    2. Mundel P
    : A role of microtubules during the formation of cell processes in neuronal and non-neuronal cells. Cell Tissue Res 291: 163–174, 1998pmid:9426305
    OpenUrlCrossRefPubMed
    1. Huber TB,
    2. Benzing T
    : The slit diaphragm: A signaling platform to regulate podocyte function. Curr Opin Nephrol Hypertens 14: 211–216, 2005pmid:15821412
    OpenUrlCrossRefPubMed
  3. ↵
    1. Garg P,
    2. Holzman LB
    : Podocytes: Gaining a foothold. Exp Cell Res 318: 955–963, 2012pmid:22421512
    OpenUrlCrossRefPubMed
  4. ↵
    1. Kobayashi N
    : Mechanism of the process formation; Podocytes vs. neurons. Microsc Res Tech 57: 217–223, 2002pmid:12012387
    OpenUrlCrossRefPubMed
  5. ↵
    1. Lennon R,
    2. Randles MJ,
    3. Humphries MJ
    : The importance of podocyte adhesion for a healthy glomerulus. Front Endocrinol (Lausanne) 5: 160, 2014pmid:25352829
    OpenUrlPubMed
  6. ↵
    1. Kriz W,
    2. Lemley KV
    : Mechanical challenges to the glomerular filtration barrier: Adaptations and pathway to sclerosis. Pediatr Nephrol 32: 405–417, 2017pmid:27008645
    OpenUrlCrossRefPubMed
  7. ↵
    1. Kriz W,
    2. Shirato I,
    3. Nagata M,
    4. LeHir M,
    5. Lemley KV
    : The podocyte’s response to stress: The enigma of foot process effacement. Am J Physiol Renal Physiol 304: F333–F347, 2013pmid:23235479
    OpenUrlAbstract/FREE Full Text
  8. ↵
    1. Drenckhahn D,
    2. Franke RP
    : Ultrastructural organization of contractile and cytoskeletal proteins in glomerular podocytes of chicken, rat, and man. Lab Invest 59: 673–682, 1988pmid:3141719
    OpenUrlPubMed
  9. ↵
    1. Andrews PM,
    2. Bates SB
    : Filamentous actin bundles in the kidney. Anat Rec 210: 1–9, 1984pmid:6486476
    OpenUrlCrossRefPubMed
  10. ↵
    1. Coles CH,
    2. Bradke F
    : Coordinating neuronal actin-microtubule dynamics. Curr Biol 25: R677–R691, 2015pmid:26241148
    OpenUrlCrossRefPubMed
  11. ↵
    1. Kaverina I,
    2. Straube A
    : Regulation of cell migration by dynamic microtubules. Semin Cell Dev Biol 22: 968–974, 2011pmid:22001384
    OpenUrlCrossRefPubMed
    1. Forth S,
    2. Kapoor TM
    : The mechanics of microtubule networks in cell division. J Cell Biol 216: 1525–1531, 2017pmid:28490474
    OpenUrlAbstract/FREE Full Text
  13. ↵
    1. Vaughan S,
    2. Dawe HR
    : Common themes in centriole and centrosome movements. Trends Cell Biol 21: 57–66, 2011pmid:20961761
    OpenUrlCrossRefPubMed
  14. ↵
    1. Kobayashi N,
    2. Reiser J,
    3. Kriz W,
    4. Kuriyama R,
    5. Mundel P
    : Nonuniform microtubular polarity established by CHO1/MKLP1 motor protein is necessary for process formation of podocytes. J Cell Biol 143: 1961–1970, 1998pmid:9864367
    OpenUrlAbstract/FREE Full Text
  15. ↵
    1. Kobayashi N,
    2. Reiser J,
    3. Schwarz K,
    4. Sakai T,
    5. Kriz W,
    6. Mundel P
    : Process formation of podocytes: Morphogenetic activity of microtubules and regulation by protein serine/threonine phosphatase PP2A. Histochem Cell Biol 115: 255–266, 2001pmid:11326753
    OpenUrlPubMed
  16. ↵
    1. Tischfield MA,
    2. Cederquist GY,
    3. Gupta ML Jr.,
    4. Engle EC
    : Phenotypic spectrum of the tubulin-related disorders and functional implications of disease-causing mutations. Curr Opin Genet Dev 21: 286–294, 2011pmid:21292473
    OpenUrlCrossRefPubMed
    1. Poirier K,
    2. Saillour Y,
    3. Bahi-Buisson N,
    4. Jaglin XH,
    5. Fallet-Bianco C,
    6. Nabbout R,
    7. Castelnau-Ptakhine L,
    8. Roubertie A,
    9. Attie-Bitach T,
    10. Desguerre I,
    11. Genevieve D,
    12. Barnerias C,
    13. Keren B,
    14. Lebrun N,
    15. Boddaert N,
    16. Encha-Razavi F,
    17. Chelly J
    : Mutations in the neuronal ß-tubulin subunit TUBB3 result in malformation of cortical development and neuronal migration defects. Hum Mol Genet 19: 4462–4473, 2010pmid:20829227
    OpenUrlCrossRefPubMed
  18. ↵
    1. Minoura I
    : Towards an understanding of the isotype-specific functions of tubulin in neurons: Technical advances in tubulin expression and purification [published online ahead of print April 12, 2017]. Neurosci Res doi: 10.1016/j.neures.2017.04.002, 2017pmid:28412269
    OpenUrlCrossRefPubMed
  19. ↵
    1. Jaglin XH,
    2. Poirier K,
    3. Saillour Y,
    4. Buhler E,
    5. Tian G,
    6. Bahi-Buisson N,
    7. Fallet-Bianco C,
    8. Phan-Dinh-Tuy F,
    9. Kong XP,
    10. Bomont P,
    11. Castelnau-Ptakhine L,
    12. Odent S,
    13. Loget P,
    14. Kossorotoff M,
    15. Snoeck I,
    16. Plessis G,
    17. Parent P,
    18. Beldjord C,
    19. Cardoso C,
    20. Represa A,
    21. Flint J,
    22. Keays DA,
    23. Cowan NJ,
    24. Chelly J
    : Mutations in the beta-tubulin gene TUBB2B result in asymmetrical polymicrogyria. Nat Genet 41: 746–752, 2009pmid:19465910
    OpenUrlCrossRefPubMed
  20. ↵
    1. Jeruschke S,
    2. Jeruschke K,
    3. DiStasio A,
    4. Karaterzi S,
    5. Büscher AK,
    6. Nalbant P,
    7. Klein-Hitpass L,
    8. Hoyer PF,
    9. Weiss J,
    10. Stottmann RW,
    11. Weber S
    : Everolimus stabilizes podocyte microtubules via enhancing TUBB2B and DCDC2 expression. PLoS One 10: e0137043, 2015pmid:26331477
    OpenUrlCrossRefPubMed
  21. ↵
    1. Parysek LM,
    2. Wolosewick JJ,
    3. Olmsted JB
    : MAP 4: A microtubule-associated protein specific for a subset of tissue microtubules. J Cell Biol 99: 2287–2296, 1984pmid:6501426
    OpenUrlAbstract/FREE Full Text
    1. Huber G,
    2. Matus A
    : Microtubule-associated protein 3 (MAP3) expression in non-neuronal tissues. J Cell Sci 95: 237–246, 1990pmid:2370278
    OpenUrlAbstract/FREE Full Text
  23. ↵
    1. Gödel M,
    2. Temerinac D,
    3. Grahammer F,
    4. Hartleben B,
    5. Kretz O,
    6. Riederer BM,
    7. Propst F,
    8. Kohl S,
    9. Huber TB
    : Microtubule Associated Protein 1b (MAP1B) is a marker of the microtubular cytoskeleton in podocytes but is not essential for the function of the kidney filtration barrier in mice. PLoS One 10: e0140116, 2015pmid:26448484
    OpenUrlCrossRefPubMed
  24. ↵
    1. Stamenkovic I,
    2. Skalli O,
    3. Gabbiani G
    : Distribution of intermediate filament proteins in normal and diseased human glomeruli. Am J Pathol 125: 465–475, 1986pmid:2432791
    OpenUrlPubMed
  25. ↵
    1. Zou J,
    2. Yaoita E,
    3. Watanabe Y,
    4. Yoshida Y,
    5. Nameta M,
    6. Li H,
    7. Qu Z,
    8. Yamamoto T
    : Upregulation of nestin, vimentin, and desmin in rat podocytes in response to injury. Virchows Arch 448: 485–492, 2006
    OpenUrlCrossRefPubMed
  26. ↵
    1. Patek CE,
    2. Fleming S,
    3. Miles CG,
    4. Bellamy CO,
    5. Ladomery M,
    6. Spraggon L,
    7. Mullins J,
    8. Hastie ND,
    9. Hooper ML
    : Murine denys-drash syndrome: Evidence of podocyte de-differentiation and systemic mediation of glomerulosclerosis. Hum Mol Genet 12: 2379–2394, 2003pmid:12915483
    OpenUrlCrossRefPubMed
  27. ↵
    1. Funk J,
    2. Ott V,
    3. Herrmann A,
    4. Rapp W,
    5. Raab S,
    6. Riboulet W,
    7. Vandjour A,
    8. Hainaut E,
    9. Benardeau A,
    10. Singer T,
    11. Jacobsen B
    : Semiautomated quantitative image analysis of glomerular immunohistochemistry markers desmin, vimentin, podocin, synaptopodin and WT-1 in acute and chronic rat kidney disease models. Histochem Cell Biol 145: 315–326, 2016pmid:26671788
    OpenUrlCrossRefPubMed
  28. ↵
    1. Embry AE,
    2. Mohammadi H,
    3. Niu X,
    4. Liu L,
    5. Moe B,
    6. Miller-Little WA,
    7. Lu CY,
    8. Bruggeman LA,
    9. McCulloch CA,
    10. Janmey PA,
    11. Miller RT
    : Biochemical and cellular determinants of renal glomerular elasticity. PLoS One 11: e0167924, 2016pmid:27942003
    OpenUrlCrossRefPubMed
  29. ↵
    1. Milner DJ,
    2. Weitzer G,
    3. Tran D,
    4. Bradley A,
    5. Capetanaki Y
    : Disruption of muscle architecture and myocardial degeneration in mice lacking desmin. J Cell Biol 134: 1255–1270, 1996pmid:8794866
    OpenUrlAbstract/FREE Full Text
  30. ↵
    1. Colucci-Guyon E,
    2. Portier MM,
    3. Dunia I,
    4. Paulin D,
    5. Pournin S,
    6. Babinet C
    : Mice lacking vimentin develop and reproduce without an obvious phenotype. Cell 79: 679–694, 1994pmid:7954832
    OpenUrlCrossRefPubMed
  31. ↵
    1. Kang YS,
    2. Li Y,
    3. Dai C,
    4. Kiss LP,
    5. Wu C,
    6. Liu Y
    : Inhibition of integrin-linked kinase blocks podocyte epithelial-mesenchymal transition and ameliorates proteinuria. Kidney Int 78: 363–373, 2010pmid:20505657
    OpenUrlCrossRefPubMed
  32. ↵
    1. Li Y,
    2. Kang YS,
    3. Dai C,
    4. Kiss LP,
    5. Wen X,
    6. Liu Y
    : Epithelial-to-mesenchymal transition is a potential pathway leading to podocyte dysfunction and proteinuria. Am J Pathol 172: 299–308, 2008pmid:18202193
    OpenUrlCrossRefPubMed
  33. ↵
    1. May CJ,
    2. Saleem M,
    3. Welsh GI
    : Podocyte dedifferentiation: A specialized process for a specialized cell. Front Endocrinol (Lausanne) 5: 148, 2014pmid:25324828
    OpenUrlPubMed
  34. ↵
    1. Perry J,
    2. Ho M,
    3. Viero S,
    4. Zheng K,
    5. Jacobs R,
    6. Thorner PS
    : The intermediate filament nestin is highly expressed in normal human podocytes and podocytes in glomerular disease. Pediatr Dev Pathol 10: 369–382, 2007
    OpenUrlCrossRefPubMed
  35. ↵
    1. Neradil J,
    2. Veselska R
    : Nestin as a marker of cancer stem cells. Cancer Sci 106: 803–811, 2015pmid:25940879
    OpenUrlCrossRefPubMed
  36. ↵
    1. Sahlgren CM,
    2. Pallari HM,
    3. He T,
    4. Chou YH,
    5. Goldman RD,
    6. Eriksson JE
    : A nestin scaffold links Cdk5/p35 signaling to oxidant-induced cell death. EMBO J 25: 4808–4819, 2006pmid:17036052
    OpenUrlAbstract/FREE Full Text
  37. ↵
    1. Park D,
    2. Xiang AP,
    3. Mao FF,
    4. Zhang L,
    5. Di CG,
    6. Liu XM,
    7. Shao Y,
    8. Ma BF,
    9. Lee JH,
    10. Ha KS,
    11. Walton N,
    12. Lahn BT
    : Nestin is required for the proper self-renewal of neural stem cells. Stem Cells 28: 2162–2171, 2010pmid:20963821
    OpenUrlCrossRefPubMed
  38. ↵
    1. Liu W,
    2. Zhang Y,
    3. Liu S,
    4. Liu Q,
    5. Hao J,
    6. Shi Y,
    7. Zhao S,
    8. Duan H
    : The expression of intermediate filament protein nestin and its association with cyclin-dependent kinase 5 in the glomeruli of rats with diabetic nephropathy. Am J Med Sci 345: 470–477, 2013pmid:23000950
    OpenUrlCrossRefPubMed
    1. Liu W,
    2. Zhang Y,
    3. Hao J,
    4. Liu S,
    5. Liu Q,
    6. Zhao S,
    7. Shi Y,
    8. Duan H
    : Nestin protects mouse podocytes against high glucose-induced apoptosis by a Cdk5-dependent mechanism. J Cell Biochem 113: 3186–3196, 2012pmid:22614921
    OpenUrlCrossRefPubMed
  40. ↵
    1. Shupp A,
    2. Casimiro MC,
    3. Pestell RG
    : Biological functions of CDK5 and potential CDK5 targeted clinical treatments. Oncotarget 8: 17373–17382, 2017pmid:28077789
    OpenUrlPubMed
  41. ↵
    1. Margiotta A,
    2. Bucci C
    : Role of intermediate filaments in vesicular traffic. Cells 5: 20, 2016pmid:27120621
    OpenUrlCrossRefPubMed
  42. ↵
    1. Campellone KG,
    2. Welch MD
    : A nucleator arms race: Cellular control of actin assembly. Nat Rev Mol Cell Biol 11: 237–251, 2010pmid:20237478
    OpenUrlCrossRefPubMed
  43. ↵
    1. Bisi S,
    2. Disanza A,
    3. Malinverno C,
    4. Frittoli E,
    5. Palamidessi A,
    6. Scita G
    : Membrane and actin dynamics interplay at lamellipodia leading edge. Curr Opin Cell Biol 25: 565–573, 2013pmid:23639310
    OpenUrlCrossRefPubMed
  44. ↵
    1. Ichimura K,
    2. Kurihara H,
    3. Sakai T
    : Actin filament organization of foot processes in rat podocytes. J Histochem Cytochem 51: 1589–1600, 2003
    OpenUrlCrossRefPubMed
  45. ↵
    1. Ichimura K,
    2. Kurihara H,
    3. Sakai T
    : Actin filament organization of foot processes in vertebrate glomerular podocytes. Cell Tissue Res 329: 541–557, 2007pmid:17605050
    OpenUrlCrossRefPubMed
  46. ↵
    1. Shirato I,
    2. Sakai T,
    3. Kimura K,
    4. Tomino Y,
    5. Kriz W
    : Cytoskeletal changes in podocytes associated with foot process effacement in Masugi nephritis. Am J Pathol 148: 1283–1296, 1996pmid:8644869
    OpenUrlPubMed
  47. ↵
    1. Makihara M,
    2. Watanabe T,
    3. Usukura E,
    4. Kaibuchi K,
    5. Narita A,
    6. Tanaka N,
    7. Usukura J
    : A new approach for the direct visualization of the membrane cytoskeleton in cryo-electron microscopy: A comparative study with freeze-etching electron microscopy. Microscopy (Oxf) 65: 488–498, 2016pmid:27587510
    OpenUrlCrossRefPubMed
  48. ↵
    1. Rigort A,
    2. Günther D,
    3. Hegerl R,
    4. Baum D,
    5. Weber B,
    6. Prohaska S,
    7. Medalia O,
    8. Baumeister W,
    9. Hege HC
    : Automated segmentation of electron tomograms for a quantitative description of actin filament networks. J Struct Biol 177: 135–144, 2012pmid:21907807
    OpenUrlCrossRefPubMed
  49. ↵
    1. Suleiman H,
    2. Zhang L,
    3. Roth R,
    4. Heuser JE,
    5. Miner JH,
    6. Shaw AS,
    7. Dani A
    : Nanoscale protein architecture of the kidney glomerular basement membrane. eLife 2: e01149, 2013pmid:24137544
    OpenUrlAbstract/FREE Full Text
  50. ↵
    1. Schell C,
    2. Wanner N,
    3. Huber TB
    : Glomerular development--shaping the multi-cellular filtration unit. Semin Cell Dev Biol 36: 39–49, 2014pmid:25153928
    OpenUrlCrossRefPubMed
  51. ↵
    1. Huber TB,
    2. Hartleben B,
    3. Winkelmann K,
    4. Schneider L,
    5. Becker JU,
    6. Leitges M,
    7. Walz G,
    8. Haller H,
    9. Schiffer M
    : Loss of podocyte aPKClambda/iota causes polarity defects and nephrotic syndrome. J Am Soc Nephrol 20: 798–806, 2009pmid:19279126
    OpenUrlAbstract/FREE Full Text
    1. Hartleben B,
    2. Schweizer H,
    3. Lübben P,
    4. Bartram MP,
    5. Möller CC,
    6. Herr R,
    7. Wei C,
    8. Neumann-Haefelin E,
    9. Schermer B,
    10. Zentgraf H,
    11. Kerjaschki D,
    12. Reiser J,
    13. Walz G,
    14. Benzing T,
    15. Huber TB
    : Neph-Nephrin proteins bind the Par3-Par6-atypical protein kinase C (aPKC) complex to regulate podocyte cell polarity. J Biol Chem 283: 23033–23038, 2008pmid:18562307
    OpenUrlAbstract/FREE Full Text
  53. ↵
    1. Hartleben B,
    2. Widmeier E,
    3. Suhm M,
    4. Worthmann K,
    5. Schell C,
    6. Helmstädter M,
    7. Wiech T,
    8. Walz G,
    9. Leitges M,
    10. Schiffer M,
    11. Huber TB
    : aPKCλ/ι and aPKCζ contribute to podocyte differentiation and glomerular maturation. J Am Soc Nephrol 24: 253–267, 2013pmid:23334392
    OpenUrlAbstract/FREE Full Text
  54. ↵
    1. Koehler S,
    2. Tellkamp F,
    3. Niessen CM,
    4. Bloch W,
    5. Kerjaschki D,
    6. Schermer B,
    7. Benzing T,
    8. Brinkkoetter PT
    : Par3A is dispensable for the function of the glomerular filtration barrier of the kidney. Am J Physiol Renal Physiol 311: F112–F119, 2016pmid:27122542
    OpenUrlAbstract/FREE Full Text
    1. Hartleben B,
    2. Widmeier E,
    3. Wanner N,
    4. Schmidts M,
    5. Kim ST,
    6. Schneider L,
    7. Mayer B,
    8. Kerjaschki D,
    9. Miner JH,
    10. Walz G,
    11. Huber TB
    : Role of the polarity protein Scribble for podocyte differentiation and maintenance. PLoS One 7: e36705, 2012pmid:22586490
    OpenUrlCrossRefPubMed
  56. ↵
    1. Akchurin O,
    2. Du Z,
    3. Ramkellawan N,
    4. Dalal V,
    5. Han SH,
    6. Pullman J,
    7. Müsch A,
    8. Susztak K,
    9. Reidy KJ
    : Partitioning-defective 1a/b depletion impairs glomerular and proximal tubule development. J Am Soc Nephrol 27: 3725–3737, 2016pmid:27185860
    OpenUrlAbstract/FREE Full Text
  57. ↵
    1. Ebarasi L,
    2. Ashraf S,
    3. Bierzynska A,
    4. Gee HY,
    5. McCarthy HJ,
    6. Lovric S,
    7. Sadowski CE,
    8. Pabst W,
    9. Vega-Warner V,
    10. Fang H,
    11. Koziell A,
    12. Simpson MA,
    13. Dursun I,
    14. Serdaroglu E,
    15. Levy S,
    16. Saleem MA,
    17. Hildebrandt F,
    18. Majumdar A
    : Defects of CRB2 cause steroid-resistant nephrotic syndrome. Am J Hum Genet 96: 153–161, 2015pmid:25557779
    OpenUrlCrossRefPubMed
  58. ↵
    1. Kaplan JM,
    2. Kim SH,
    3. North KN,
    4. Rennke H,
    5. Correia LA,
    6. Tong HQ,
    7. Mathis BJ,
    8. Rodríguez-Pérez JC,
    9. Allen PG,
    10. Beggs AH,
    11. Pollak MR
    : Mutations in ACTN4, encoding alpha-actinin-4, cause familial focal segmental glomerulosclerosis. Nat Genet 24: 251–256, 2000pmid:10700177
    OpenUrlCrossRefPubMed
  59. ↵
    1. Gautel M,
    2. Djinović-Carugo K
    : The sarcomeric cytoskeleton: From molecules to motion. J Exp Biol 219: 135–145, 2016pmid:26792323
    OpenUrlAbstract/FREE Full Text
  60. ↵
    1. Bartram MP,
    2. Habbig S,
    3. Pahmeyer C,
    4. Höhne M,
    5. Weber LT,
    6. Thiele H,
    7. Altmüller J,
    8. Kottoor N,
    9. Wenzel A,
    10. Krueger M,
    11. Schermer B,
    12. Benzing T,
    13. Rinschen MM,
    14. Beck BB
    : Three-layered proteomic characterization of a novel ACTN4 mutation unravels its pathogenic potential in FSGS. Hum Mol Genet 25: 1152–1164, 2016pmid:26740551
    OpenUrlCrossRefPubMed
  61. ↵
    1. Weins A,
    2. Kenlan P,
    3. Herbert S,
    4. Le TC,
    5. Villegas I,
    6. Kaplan BS,
    7. Appel GB,
    8. Pollak MR
    : Mutational and biological analysis of alpha-actinin-4 in focal segmental glomerulosclerosis. J Am Soc Nephrol 16: 3694–3701, 2005pmid:16251236
    OpenUrlAbstract/FREE Full Text
  62. ↵
    1. Michaud JL,
    2. Chaisson KM,
    3. Parks RJ,
    4. Kennedy CR
    : FSGS-associated alpha-actinin-4 (K256E) impairs cytoskeletal dynamics in podocytes. Kidney Int 70: 1054–1061, 2006pmid:16837921
    OpenUrlCrossRefPubMed
  63. ↵
    1. Kos CH,
    2. Le TC,
    3. Sinha S,
    4. Henderson JM,
    5. Kim SH,
    6. Sugimoto H,
    7. Kalluri R,
    8. Gerszten RE,
    9. Pollak MR
    : Mice deficient in alpha-actinin-4 have severe glomerular disease. J Clin Invest 111: 1683–1690, 2003pmid:12782671
    OpenUrlCrossRefPubMed
  64. ↵
    1. Zhao X,
    2. Hsu KS,
    3. Lim JH,
    4. Bruggeman LA,
    5. Kao HY
    : α-Actinin 4 potentiates nuclear factor κ-light-chain-enhancer of activated B-cell (NF-κB) activity in podocytes independent of its cytoplasmic actin binding function. J Biol Chem 290: 338–349, 2015pmid:25411248
    OpenUrlAbstract/FREE Full Text
  65. ↵
    1. Shekhar S,
    2. Pernier J,
    3. Carlier MF
    : Regulators of actin filament barbed ends at a glance. J Cell Sci 129: 1085–1091, 2016pmid:26940918
    OpenUrlAbstract/FREE Full Text
  66. ↵
    1. Sun H,
    2. Al-Romaih KI,
    3. MacRae CA,
    4. Pollak MR
    : Human kidney disease-causing INF2 mutations perturb Rho/Dia signaling in the glomerulus. EBioMedicine 1: 107–115, 2014pmid:26086034
    OpenUrlCrossRefPubMed
  67. ↵
    1. Rollason R,
    2. Wherlock M,
    3. Heath JA,
    4. Heesom KJ,
    5. Saleem MA,
    6. Welsh GI
    : Disease causing mutations in inverted formin 2 regulate its binding to G-actin, F-actin capping protein (CapZ α-1) and profilin 2. Biosci Rep 36: e00302, 2016pmid:26764407
    OpenUrlAbstract/FREE Full Text
  68. ↵
    1. Boyer O,
    2. Nevo F,
    3. Plaisier E,
    4. Funalot B,
    5. Gribouval O,
    6. Benoit G,
    7. Huynh Cong E,
    8. Arrondel C,
    9. Tête MJ,
    10. Montjean R,
    11. Richard L,
    12. Karras A,
    13. Pouteil-Noble C,
    14. Balafrej L,
    15. Bonnardeaux A,
    16. Canaud G,
    17. Charasse C,
    18. Dantal J,
    19. Deschenes G,
    20. Deteix P,
    21. Dubourg O,
    22. Petiot P,
    23. Pouthier D,
    24. Leguern E,
    25. Guiochon-Mantel A,
    26. Broutin I,
    27. Gubler MC,
    28. Saunier S,
    29. Ronco P,
    30. Vallat JM,
    31. Alonso MA,
    32. Antignac C,
    33. Mollet G
    : INF2 mutations in Charcot-Marie-Tooth disease with glomerulopathy. N Engl J Med 365: 2377–2388, 2011pmid:22187985
    OpenUrlCrossRefPubMed
  69. ↵
    1. Korobova F,
    2. Ramabhadran V,
    3. Higgs HN
    : An actin-dependent step in mitochondrial fission mediated by the ER-associated formin INF2. Science 339: 464–467, 2013pmid:23349293
    OpenUrlAbstract/FREE Full Text
  70. ↵
    1. Kobayashi N,
    2. Gao SY,
    3. Chen J,
    4. Saito K,
    5. Miyawaki K,
    6. Li CY,
    7. Pan L,
    8. Saito S,
    9. Terashita T,
    10. Matsuda S
    : Process formation of the renal glomerular podocyte: Is there common molecular machinery for processes of podocytes and neurons? Anat Sci Int 79: 1–10, 2004pmid:15088787
    OpenUrlCrossRefPubMed
  71. ↵
    1. Wu C,
    2. Jiao H,
    3. Lai Y,
    4. Zheng W,
    5. Chen K,
    6. Qu H,
    7. Deng W,
    8. Song P,
    9. Zhu K,
    10. Cao H,
    11. Galson DL,
    12. Fan J,
    13. Im HJ,
    14. Liu Y,
    15. Chen J,
    16. Chen D,
    17. Xiao G
    : Kindlin-2 controls TGF-β signalling and Sox9 expression to regulate chondrogenesis. Nat Commun 6: 7531, 2015pmid:26151572
    OpenUrlCrossRefPubMed
  72. ↵
    1. Kim JM,
    2. Wu H,
    3. Green G,
    4. Winkler CA,
    5. Kopp JB,
    6. Miner JH,
    7. Unanue ER,
    8. Shaw AS
    : CD2-associated protein haploinsufficiency is linked to glomerular disease susceptibility. Science 300: 1298–1300, 2003pmid:12764198
    OpenUrlAbstract/FREE Full Text
    1. Tsvetkov D,
    2. Hohmann M,
    3. Anistan YM,
    4. Mannaa M,
    5. Harteneck C,
    6. Rudolph B,
    7. Gollasch M
    : A CD2AP mutation associated with focal segmental glomerulosclerosis in young adulthood. Clin Med Insights Case Rep 9: 15–19, 2016pmid:26997877
    OpenUrlPubMed
    1. Benoit G,
    2. Machuca E,
    3. Nevo F,
    4. Gribouval O,
    5. Lepage D,
    6. Antignac C
    : Analysis of recessive CD2AP and ACTN4 mutations in steroid-resistant nephrotic syndrome. Pediatr Nephrol 25: 445–451, 2010pmid:19956976
    OpenUrlCrossRefPubMed
  75. ↵
    1. Löwik MM,
    2. Groenen PJ,
    3. Pronk I,
    4. Lilien MR,
    5. Goldschmeding R,
    6. Dijkman HB,
    7. Levtchenko EN,
    8. Monnens LA,
    9. van den Heuvel LP
    : Focal segmental glomerulosclerosis in a patient homozygous for a CD2AP mutation. Kidney Int 72: 1198–1203, 2007pmid:17713465
    OpenUrlCrossRefPubMed
  76. ↵
    1. Grunkemeyer JA,
    2. Kwoh C,
    3. Huber TB,
    4. Shaw AS
    : CD2-associated protein (CD2AP) expression in podocytes rescues lethality of CD2AP deficiency. J Biol Chem 280: 29677–29681, 2005pmid:15951437
    OpenUrlAbstract/FREE Full Text
  77. ↵
    1. Dustin ML,
    2. Olszowy MW,
    3. Holdorf AD,
    4. Li J,
    5. Bromley S,
    6. Desai N,
    7. Widder P,
    8. Rosenberger F,
    9. van der Merwe PA,
    10. Allen PM,
    11. Shaw AS
    : A novel adaptor protein orchestrates receptor patterning and cytoskeletal polarity in T-cell contacts. Cell 94: 667–677, 1998pmid:9741631
    OpenUrlCrossRefPubMed
  78. ↵
    1. Huber TB,
    2. Hartleben B,
    3. Kim J,
    4. Schmidts M,
    5. Schermer B,
    6. Keil A,
    7. Egger L,
    8. Lecha RL,
    9. Borner C,
    10. Pavenstädt H,
    11. Shaw AS,
    12. Walz G,
    13. Benzing T
    : Nephrin and CD2AP associate with phosphoinositide 3-OH kinase and stimulate AKT-dependent signaling. Mol Cell Biol 23: 4917–4928, 2003pmid:12832477
    OpenUrlAbstract/FREE Full Text
  79. ↵
    1. Wasik AA,
    2. Polianskyte-Prause Z,
    3. Dong MQ,
    4. Shaw AS,
    5. Yates JR III,
    6. Farquhar MG,
    7. Lehtonen S
    : Septin 7 forms a complex with CD2AP and nephrin and regulates glucose transporter trafficking. Mol Biol Cell 23: 3370–3379, 2012pmid:22809625
    OpenUrlAbstract/FREE Full Text
  80. ↵
    1. Yaddanapudi S,
    2. Altintas MM,
    3. Kistler AD,
    4. Fernandez I,
    5. Möller CC,
    6. Wei C,
    7. Peev V,
    8. Flesche JB,
    9. Forst AL,
    10. Li J,
    11. Patrakka J,
    12. Xiao Z,
    13. Grahammer F,
    14. Schiffer M,
    15. Lohmüller T,
    16. Reinheckel T,
    17. Gu C,
    18. Huber TB,
    19. Ju W,
    20. Bitzer M,
    21. Rastaldi MP,
    22. Ruiz P,
    23. Tryggvason K,
    24. Shaw AS,
    25. Faul C,
    26. Sever S,
    27. Reiser J
    : CD2AP in mouse and human podocytes controls a proteolytic program that regulates cytoskeletal structure and cellular survival. J Clin Invest 121: 3965–3980, 2011pmid:21911934
    OpenUrlCrossRefPubMed
  81. ↵
    1. Akilesh S,
    2. Suleiman H,
    3. Yu H,
    4. Stander MC,
    5. Lavin P,
    6. Gbadegesin R,
    7. Antignac C,
    8. Pollak M,
    9. Kopp JB,
    10. Winn MP,
    11. Shaw AS
    : Arhgap24 inactivates Rac1 in mouse podocytes, and a mutant form is associated with familial focal segmental glomerulosclerosis. J Clin Invest 121: 4127–4137, 2011pmid:21911940
    OpenUrlCrossRefPubMed
  82. ↵
    1. Huber TB,
    2. Kwoh C,
    3. Wu H,
    4. Asanuma K,
    5. Gödel M,
    6. Hartleben B,
    7. Blumer KJ,
    8. Miner JH,
    9. Mundel P,
    10. Shaw AS
    : Bigenic mouse models of focal segmental glomerulosclerosis involving pairwise interaction of CD2AP, Fyn, and synaptopodin. J Clin Invest 116: 1337–1345, 2006pmid:16628251
    OpenUrlCrossRefPubMed
  83. ↵
    1. Endlich N,
    2. Simon O,
    3. Göpferich A,
    4. Wegner H,
    5. Moeller MJ,
    6. Rumpel E,
    7. Kotb AM,
    8. Endlich K
    : Two-photon microscopy reveals stationary podocytes in living zebrafish larvae. J Am Soc Nephrol 25: 681–686, 2014pmid:24309184
    OpenUrlAbstract/FREE Full Text
  84. ↵
    1. Hackl MJ,
    2. Burford JL,
    3. Villanueva K,
    4. Lam L,
    5. Suszták K,
    6. Schermer B,
    7. Benzing T,
    8. Peti-Peterdi J
    : Tracking the fate of glomerular epithelial cells in vivo using serial multiphoton imaging in new mouse models with fluorescent lineage tags. Nat Med 19: 1661–1666, 2013pmid:24270544
    OpenUrlCrossRefPubMed
  85. ↵
    1. Reiser J,
    2. Oh J,
    3. Shirato I,
    4. Asanuma K,
    5. Hug A,
    6. Mundel TM,
    7. Honey K,
    8. Ishidoh K,
    9. Kominami E,
    10. Kreidberg JA,
    11. Tomino Y,
    12. Mundel P
    : Podocyte migration during nephrotic syndrome requires a coordinated interplay between cathepsin L and alpha3 integrin. J Biol Chem 279: 34827–34832, 2004pmid:15197181
    OpenUrlAbstract/FREE Full Text
  86. ↵
    1. Brähler S,
    2. Yu H,
    3. Suleiman H,
    4. Krishnan GM,
    5. Saunders BT,
    6. Kopp JB,
    7. Miner JH,
    8. Zinselmeyer BH,
    9. Shaw AS
    : Intravital and kidney slice smaging of podocyte membrane dynamics. J Am Soc Nephrol 27: 3285–3290, 2016pmid:27036737
    OpenUrlAbstract/FREE Full Text
  87. ↵
    1. Yu H,
    2. Suleiman H,
    3. Kim AH,
    4. Miner JH,
    5. Dani A,
    6. Shaw AS,
    7. Akilesh S
    : Rac1 activation in podocytes induces rapid foot process effacement and proteinuria. Mol Cell Biol 33: 4755–4764, 2013pmid:24061480
    OpenUrlAbstract/FREE Full Text
  88. ↵
    1. Scott RP,
    2. Hawley SP,
    3. Ruston J,
    4. Du J,
    5. Brakebusch C,
    6. Jones N,
    7. Pawson T
    : Podocyte-specific loss of Cdc42 leads to congenital nephropathy. J Am Soc Nephrol 23: 1149–1154, 2012pmid:22518006
    OpenUrlAbstract/FREE Full Text
  89. ↵
    1. Blattner SM,
    2. Hodgin JB,
    3. Nishio M,
    4. Wylie SA,
    5. Saha J,
    6. Soofi AA,
    7. Vining C,
    8. Randolph A,
    9. Herbach N,
    10. Wanke R,
    11. Atkins KB,
    12. Gyung Kang H,
    13. Henger A,
    14. Brakebusch C,
    15. Holzman LB,
    16. Kretzler M
    : Divergent functions of the Rho GTPases Rac1 and Cdc42 in podocyte injury. Kidney Int 84: 920–930, 2013pmid:23677246
    OpenUrlCrossRefPubMed
  90. ↵
    1. Mesa Latorre J,
    2. de Dios García Díaz J,
    3. Larregla Garraus S,
    4. Ortiz Conde MC
    : [Nodular regenerative hyperplasia of the liver and acute lymphoblastic leukemia]. Rev Clin Esp 186: 192–193, 1990pmid:2367724
    OpenUrlPubMed
  91. ↵
    1. Gee HY,
    2. Saisawat P,
    3. Ashraf S,
    4. Hurd TW,
    5. Vega-Warner V,
    6. Fang H,
    7. Beck BB,
    8. Gribouval O,
    9. Zhou W,
    10. Diaz KA,
    11. Natarajan S,
    12. Wiggins RC,
    13. Lovric S,
    14. Chernin G,
    15. Schoeb DS,
    16. Ovunc B,
    17. Frishberg Y,
    18. Soliman NA,
    19. Fathy HM,
    20. Goebel H,
    21. Hoefele J,
    22. Weber LT,
    23. Innis JW,
    24. Faul C,
    25. Han Z,
    26. Washburn J,
    27. Antignac C,
    28. Levy S,
    29. Otto EA,
    30. Hildebrandt F
    : ARHGDIA mutations cause nephrotic syndrome via defective RHO GTPase signaling. J Clin Invest 123: 3243–3253, 2013pmid:23867502
    OpenUrlCrossRefPubMed
  92. ↵
    1. Shibata S,
    2. Nagase M,
    3. Yoshida S,
    4. Kawarazaki W,
    5. Kurihara H,
    6. Tanaka H,
    7. Miyoshi J,
    8. Takai Y,
    9. Fujita T
    : Modification of mineralocorticoid receptor function by Rac1 GTPase: Implication in proteinuric kidney disease. Nat Med 14: 1370–1376, 2008pmid:19029984
    OpenUrlCrossRefPubMed
  93. ↵
    1. Kriz W,
    2. Lemley KV
    : A potential role for mechanical forces in the detachment of podocytes and the progression of CKD. J Am Soc Nephrol 26: 258–269, 2015pmid:25060060
    OpenUrlAbstract/FREE Full Text
  94. ↵
    1. Winograd-Katz SE,
    2. Fässler R,
    3. Geiger B,
    4. Legate KR
    : The integrin adhesome: From genes and proteins to human disease. Nat Rev Mol Cell Biol 15: 273–288, 2014pmid:24651544
    OpenUrlCrossRefPubMed
  95. ↵
    1. Has C,
    2. Spartà G,
    3. Kiritsi D,
    4. Weibel L,
    5. Moeller A,
    6. Vega-Warner V,
    7. Waters A,
    8. He Y,
    9. Anikster Y,
    10. Esser P,
    11. Straub BK,
    12. Hausser I,
    13. Bockenhauer D,
    14. Dekel B,
    15. Hildebrandt F,
    16. Bruckner-Tuderman L,
    17. Laube GF
    : Integrin α3 mutations with kidney, lung, and skin disease. N Engl J Med 366: 1508–1514, 2012pmid:22512483
    OpenUrlCrossRefPubMed
  96. ↵
    1. Nicolaou N,
    2. Margadant C,
    3. Kevelam SH,
    4. Lilien MR,
    5. Oosterveld MJ,
    6. Kreft M,
    7. van Eerde AM,
    8. Pfundt R,
    9. Terhal PA,
    10. van der Zwaag B,
    11. Nikkels PG,
    12. Sachs N,
    13. Goldschmeding R,
    14. Knoers NV,
    15. Renkema KY,
    16. Sonnenberg A
    : Gain of glycosylation in integrin α3 causes lung disease and nephrotic syndrome. J Clin Invest 122: 4375–4387, 2012pmid:23114595
    OpenUrlCrossRefPubMed
  97. ↵
    1. Geiger B,
    2. Spatz JP,
    3. Bershadsky AD
    : Environmental sensing through focal adhesions. Nat Rev Mol Cell Biol 10: 21–33, 2009pmid:19197329
    OpenUrlCrossRefPubMed
  98. ↵
    1. Schiller HB,
    2. Friedel CC,
    3. Boulegue C,
    4. Fässler R
    : Quantitative proteomics of the integrin adhesome show a myosin II-dependent recruitment of LIM domain proteins. EMBO Rep 12: 259–266, 2011pmid:21311561
    OpenUrlAbstract/FREE Full Text
  99. ↵
    1. Horton ER,
    2. Byron A,
    3. Askari JA,
    4. Ng DHJ,
    5. Millon-Frémillon A,
    6. Robertson J,
    7. Koper EJ,
    8. Paul NR,
    9. Warwood S,
    10. Knight D,
    11. Humphries JD,
    12. Humphries MJ
    : Definition of a consensus integrin adhesome and its dynamics during adhesion complex assembly and disassembly. Nat Cell Biol 17: 1577–1587, 2015pmid:26479319
    OpenUrlCrossRefPubMed
  100. ↵
    1. Sachs N,
    2. Sonnenberg A
    : Cell-matrix adhesion of podocytes in physiology and disease. Nat Rev Nephrol 9: 200–210, 2013pmid:23338211
    OpenUrlCrossRefPubMed
  101. ↵
    1. Kanasaki K,
    2. Kanda Y,
    3. Palmsten K,
    4. Tanjore H,
    5. Lee SB,
    6. Lebleu VS,
    7. Gattone VH Jr.,
    8. Kalluri R
    : Integrin beta1-mediated matrix assembly and signaling are critical for the normal development and function of the kidney glomerulus. Dev Biol 313: 584–593, 2008pmid:18082680
    OpenUrlCrossRefPubMed
  102. ↵
    1. Kreidberg JA,
    2. Donovan MJ,
    3. Goldstein SL,
    4. Rennke H,
    5. Shepherd K,
    6. Jones RC,
    7. Jaenisch R
    : Alpha 3 beta 1 integrin has a crucial role in kidney and lung organogenesis. Development 122: 3537–3547, 1996pmid:8951069
    OpenUrlAbstract
  103. ↵
    1. Yu CC,
    2. Fornoni A,
    3. Weins A,
    4. Hakroush S,
    5. Maiguel D,
    6. Sageshima J,
    7. Chen L,
    8. Ciancio G,
    9. Faridi MH,
    10. Behr D,
    11. Campbell KN,
    12. Chang JM,
    13. Chen HC,
    14. Oh J,
    15. Faul C,
    16. Arnaout MA,
    17. Fiorina P,
    18. Gupta V,
    19. Greka A,
    20. Burke GW III,
    21. Mundel P
    : Abatacept in B7-1-positive proteinuric kidney disease. N Engl J Med 369: 2416–2423, 2013pmid:24206430
    OpenUrlCrossRefPubMed
  104. ↵
    1. Wei C,
    2. El Hindi S,
    3. Li J,
    4. Fornoni A,
    5. Goes N,
    6. Sageshima J,
    7. Maiguel D,
    8. Karumanchi SA,
    9. Yap HK,
    10. Saleem M,
    11. Zhang Q,
    12. Nikolic B,
    13. Chaudhuri A,
    14. Daftarian P,
    15. Salido E,
    16. Torres A,
    17. Salifu M,
    18. Sarwal MM,
    19. Schaefer F,
    20. Morath C,
    21. Schwenger V,
    22. Zeier M,
    23. Gupta V,
    24. Roth D,
    25. Rastaldi MP,
    26. Burke G,
    27. Ruiz P,
    28. Reiser J
    : Circulating urokinase receptor as a cause of focal segmental glomerulosclerosis. Nat Med 17: 952–960, 2011pmid:21804539
    OpenUrlCrossRefPubMed
  105. ↵
    1. Schell C,
    2. Rogg M,
    3. Suhm M,
    4. Helmstädter M,
    5. Sellung D,
    6. Yasuda-Yamahara M,
    7. Kretz O,
    8. Küttner V,
    9. Suleiman H,
    10. Kollipara L,
    11. Zahedi RP,
    12. Sickmann A,
    13. Eimer S,
    14. Shaw AS,
    15. Kramer-Zucker A,
    16. Hirano-Kobayashi M,
    17. Abe T,
    18. Aizawa S,
    19. Grahammer F,
    20. Hartleben B,
    21. Dengjel J,
    22. Huber TB
    : The FERM protein EPB41L5 regulates actomyosin contractility and focal adhesion formation to maintain the kidney filtration barrier. Proc Natl Acad Sci U S A 114: E4621–E4630, 2017pmid:28536193
    OpenUrlAbstract/FREE Full Text
  106. ↵
    1. Schiffer M,
    2. Teng B,
    3. Gu C,
    4. Shchedrina VA,
    5. Kasaikina M,
    6. Pham VA,
    7. Hanke N,
    8. Rong S,
    9. Gueler F,
    10. Schroder P,
    11. Tossidou I,
    12. Park JK,
    13. Staggs L,
    14. Haller H,
    15. Erschow S,
    16. Hilfiker-Kleiner D,
    17. Wei C,
    18. Chen C,
    19. Tardi N,
    20. Hakroush S,
    21. Selig MK,
    22. Vasilyev A,
    23. Merscher S,
    24. Reiser J,
    25. Sever S
    : Pharmacological targeting of actin-dependent dynamin oligomerization ameliorates chronic kidney disease in diverse animal models. Nat Med 21: 601–609, 2015pmid:25962121
    OpenUrlCrossRefPubMed
  107. ↵
    1. Soda K,
    2. Balkin DM,
    3. Ferguson SM,
    4. Paradise S,
    5. Milosevic I,
    6. Giovedi S,
    7. Volpicelli-Daley L,
    8. Tian X,
    9. Wu Y,
    10. Ma H,
    11. Son SH,
    12. Zheng R,
    13. Moeckel G,
    14. Cremona O,
    15. Holzman LB,
    16. De Camilli P,
    17. Ishibe S
    : Role of dynamin, synaptojanin, and endophilin in podocyte foot processes. J Clin Invest 122: 4401–4411, 2012pmid:23187129
    OpenUrlCrossRefPubMed
  108. ↵
    1. Gu C,
    2. Lee HW,
    3. Garborcauskas G,
    4. Reiser J,
    5. Gupta V,
    6. Sever S
    : Dynamin autonomously regulates podocyte focal adhesion maturation. J Am Soc Nephrol 28: 446–451, 2017pmid:27432739
    OpenUrlAbstract/FREE Full Text
    1. Gbadegesin RA,
    2. Hall G,
    3. Adeyemo A,
    4. Hanke N,
    5. Tossidou I,
    6. Burchette J,
    7. Wu G,
    8. Homstad A,
    9. Sparks MA,
    10. Gomez J,
    11. Jiang R,
    12. Alonso A,
    13. Lavin P,
    14. Conlon P,
    15. Korstanje R,
    16. Stander MC,
    17. Shamsan G,
    18. Barua M,
    19. Spurney R,
    20. Singhal PC,
    21. Kopp JB,
    22. Haller H,
    23. Howell D,
    24. Pollak MR,
    25. Shaw AS,
    26. Schiffer M,
    27. Winn MP
    : Mutations in the gene that encodes the F-actin binding protein anillin cause FSGS. J Am Soc Nephrol 25: 1991–2002, 2014pmid:24676636
    OpenUrlAbstract/FREE Full Text
    1. Brown EJ,
    2. Schlöndorff JS,
    3. Becker DJ,
    4. Tsukaguchi H,
    5. Tonna SJ,
    6. Uscinski AL,
    7. Higgs HN,
    8. Henderson JM,
    9. Pollak MR
    : Mutations in the formin gene INF2 cause focal segmental glomerulosclerosis. Nat Genet 42: 72–76, 2010pmid:20023659
    OpenUrlCrossRefPubMed
    1. Subramanian B,
    2. Sun H,
    3. Yan P,
    4. Charoonratana VT,
    5. Higgs HN,
    6. Wang F,
    7. Lai KV,
    8. Valenzuela DM,
    9. Brown EJ,
    10. Schlöndorff JS,
    11. Pollak MR
    : Mice with mutant Inf2 show impaired podocyte and slit diaphragm integrity in response to protamine-induced kidney injury. Kidney Int 90: 363–372, 2016pmid:27350175
    OpenUrlCrossRefPubMed
    1. Gee HY,
    2. Zhang F,
    3. Ashraf S,
    4. Kohl S,
    5. Sadowski CE,
    6. Vega-Warner V,
    7. Zhou W,
    8. Lovric S,
    9. Fang H,
    10. Nettleton M,
    11. Zhu JY,
    12. Hoefele J,
    13. Weber LT,
    14. Podracka L,
    15. Boor A,
    16. Fehrenbach H,
    17. Innis JW,
    18. Washburn J,
    19. Levy S,
    20. Lifton RP,
    21. Otto EA,
    22. Han Z,
    23. Hildebrandt F
    : KANK deficiency leads to podocyte dysfunction and nephrotic syndrome. J Clin Invest 125: 2375–2384, 2015pmid:25961457
    OpenUrlCrossRefPubMed
    1. Kopp JB,
    2. Smith MW,
    3. Nelson GW,
    4. Johnson RC,
    5. Freedman BI,
    6. Bowden DW,
    7. Oleksyk T,
    8. McKenzie LM,
    9. Kajiyama H,
    10. Ahuja TS,
    11. Berns JS,
    12. Briggs W,
    13. Cho ME,
    14. Dart RA,
    15. Kimmel PL,
    16. Korbet SM,
    17. Michel DM,
    18. Mokrzycki MH,
    19. Schelling JR,
    20. Simon E,
    21. Trachtman H,
    22. Vlahov D,
    23. Winkler CA
    : MYH9 is a major-effect risk gene for focal segmental glomerulosclerosis. Nat Genet 40: 1175–1184, 2008pmid:18794856
    OpenUrlCrossRefPubMed
    1. Ghiggeri GM,
    2. Caridi G,
    3. Magrini U,
    4. Sessa A,
    5. Savoia A,
    6. Seri M,
    7. Pecci A,
    8. Romagnoli R,
    9. Gangarossa S,
    10. Noris P,
    11. Sartore S,
    12. Necchi V,
    13. Ravazzolo R,
    14. Balduini CL
    : Genetics, clinical and pathological features of glomerulonephritis associated with mutations of nonmuscle myosin IIA (Fechtner syndrome). Am J Kidney Dis 41: 95–104, 2003pmid:12500226
    OpenUrlCrossRefPubMed
View Abstract
Back to top

In this issue

View Selected Citations (0)
Print
Download PDF
Article Alerts
Email Article
Citation Tools
Request Permissions
The Evolving Complexity of the Podocyte Cytoskeleton
Christoph Schell, Tobias B. Huber
JASN Nov 2017, 28 (11) 3166-3174; DOI: 10.1681/ASN.2017020143
del.icio.us logo Digg logo Reddit logo Twitter logo CiteULike logo Facebook logo Google logo Mendeley logo

Jump to section

Keywords